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Background: 4-Aminoquinoline SGI-1027 and analogs inhibit DNA methylation, which is deregulated in cancers.
Results:These compounds induce deviations fromMichaelis-Menten equations inDNA competition experiments and interact
with DNA.
Conclusion:They are competitive inhibitors for the DNA substrate of the DNAmethyltransferase and non-competitive for the
methyl group donor, S-adenosyl-L-methionine.
Significance: These findings suggest a mechanism of inhibition for these 4-aminoquinoline-based DNMT inhibitors.
Among the epigenetic marks, DNA methylation is one of the
most studied. It is highly deregulated in numerous diseases,
including cancer. Indeed, it has been shown that hypermethyla-
tion of tumor suppressor genes promoters is a common feature
of cancer cells. BecauseDNAmethylation is reversible, theDNA
methyltransferases (DNMTs), responsible for this epigenetic
mark, are considered promising therapeutic targets. Several
molecules have been identified asDNMT inhibitors and, among
the non-nucleoside inhibitors, 4-aminoquinoline-based inhibi-
tors, such as SGI-1027 and its analogs, showed potent inhibitory
activity. Here we characterized the in vitromechanism of action
of SGI-1027 and two analogs. Enzymatic competition studies
with the DNA substrate and the methyl donor cofactor, S-ad-
enosyl-L-methionine (AdoMet), displayed AdoMet non-com-
petitive and DNA competitive behavior. In addition, deviations
from theMichaelis-Menten model in DNA competition experi-
ments suggested an interaction with DNA. Thus their ability to
interact with DNA was established; although SGI-1027 was a
weak DNA ligand, analog 5, the most potent inhibitor, strongly
interacted with DNA. Finally, as 5 interacted with DNMT only
when the DNA duplex was present, we hypothesize that this
class of chemical compounds inhibit DNMTs by interacting
with the DNA substrate.
Methylation of cytosine residues in DNA, occurring in
humans at CpG sites, is an important epigenetic mark highly
deregulated in cancer (1). Indeed, hypermethylation of
tumor suppressor genes promoters is a common feature of
cancer cells and leads to abnormal silencing of the targeted
genes. Because it is a reversible phenomenon, DNA methyl-
transferases (DNMTs),3 which catalyze the transfer of a
methyl group from S-adenosyl-L-methionine (AdoMet) to
the C5-position of cytosine, are promising therapeutic tar-
gets (2).
DNMTs are divided into two categories: DNMT1, which is
mainly involved in the maintenance of the methylation pattern
and is active on hemimethylated DNA, and DNMT3s, which
are active both on unmethylated and hemimethylated sub-
strates, are responsible of de novo DNA methylation, and
include DNMT3A, DNMT3B, and the catalytically inactive
DNMT3L (3).
Several inhibitors of these enzymes have been described and
reviewed in numerous publications (4–6). The nucleoside ana-
logs azacitidine (Vidaza) and decitabine (Dacogen) have been
approved by the Food and Drug Administration in 2004 and
2006, respectively, for hematological malignancies, whereas
some other nucleoside-like analogs are currently in clinical tri-
als in hematological diseases and solid tumors (5, 7, 8). How-
ever, their poor bioavailability, their chemical instability in
physiological media, and their lack of selectivity reveal an
urgent need for novel, more selective and non-nucleoside
inhibitors. Among these, various inhibitors have been charac-
terized, but most of them are nonspecific and/or do not induce
DNAdemethylation in cells (5, 6), except for SGI-1027, a quin-
oline derivative that was described by Datta et al. in 2009 (9) for
its enzymatic and cellular DNMT inhibition.
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Initially synthesized as part of a minor-groove binders
family of quinolinium bisquaternary salts, SGI-1027 inhibits
bacterial DNA methyltransferase M.SssI, human DNMT1,
mouse Dnmt3A, and mouse Dnmt3B (9). It is currently the
reference compound in several DNMT inhibition assays (10,
11) and structure-activity relationship studies (12). Therefore,
there is an actual interest in elucidating its molecular mecha-
nism of action.
Two groups performed competition studies on DNMT1 (9,
10) and concluded that SGI-1027 was a AdoMet-competitive
and DNA non-competitive inhibitor of DNMT1. Here, we
studied the mechanism of inhibition of full-length human
DNMT1 by SGI-1027 and two analogs that we recently syn-
thesized (compounds 5 and 31 in Fig. 1, described by Valente
et al. (13) and Rilova et al. (14), respectively). In contrast to
previously reported data (9, 10), our findings clearly support
a behavior as DNA competitive and AdoMet non-competi-
tive inhibitors. The ability of the compounds to interact with
DNA and DNMT1 was investigated to further characterize
the mechanism of action using compound 19 (Fig. 1) as a
negative control as it did not succeed to inhibit either
DNMT1 or human catalytic DNMT3A (DNMT3Acat) (14).
Several hypotheses are described, and the differences with
the literature are discussed.
EXPERIMENTAL PROCEDURES
General—All commercially available reagents and sol-
vents were purchased from Sigma, and radioactive [methyl-
3H]AdoMet was from PerkinElmer Life Sciences. SGI-1027,
compounds 19 and 31, and compound 5 were synthesized as
described in Refs. 9, 14, and 13, respectively. 10 mM stock solu-
tions were prepared in DMSO and aliquoted. The compounds
were named according to the nomenclature of the respective
articles.
Enzyme Production—Full-length histidine-tagged human
DNMT1 (182 kDa) was produced and purified according to Lee
et al. (15). Catalytic human DNMT3Acat (DNMT3Acat: resi-
dues 623–908 amino acids) was produced and purified accord-
ing to Gros et al. (16).
DNMT Inhibition Assays—DNMT1 inhibition assay was
developed and described in Gros et al. (16). DNMT3Acat inhi-
bition was described in Rilova et al. (14).
DNMT1 Competition Assays—Competition assays on full-
length DNMT1 were realized according to Gros et al. (16).
Briefly, the tested compound, biotinylated duplex, [methyl-
3H]AdoMet and DNMT1 were incubated for 2 h in 10 l at
37 °C. An aliquot of 8l was then transferred in a FlashplateTM
well containing 190 l of 20 M SAH solution in Tris-HCl. The
FlashplateTMwas agitated at room temperature for 1 h, washed
3 timeswith 200l of 0.05%Tween 20 inTris-HCl, and read in
200 l of Tris-HCl on TopCount NXT.
In AdoMet competition assays, [methyl-3H]AdoMet was
varied between 0.5 and 15 M at a fixed DNA duplex concen-
tration of 0.6 M. For each AdoMet concentration the tested
compound concentration was adjusted between its IC10 and
IC80. For each compound concentration, the Michaelis-
Menten model was fitted by non-linear regression to the
data, and Kmapp and Vmapp were calculated according to this
model. For Lineweaver-Burk plots, a linear model was fitted
by linear regression to the transformed data. Lineweaver-
Burk or double-reciprocal plots were only used as a graphic
representation to distinguish competitive, non-competitive,
and uncompetitive inhibitor. Noteworthy, this graphic rep-
resentation is known to distort and magnify the errors of the
data.
In DNA-competition assays, the DNA duplex concentration
was varied between 0.05 and 0.6 M, whereas [methyl-
3H]AdoMet concentration was held at 15 M. For each DNA
duplex concentration, the tested compound concentration was
adjusted between its IC10 and IC80 values. For each compound
concentration, the Copeland and Horiuchi (17) non-competi-
tive, uncompetitive, and competitive models were fitted by
non-linear regression to the data. For each molecule, the only
convergent model at each concentration was the Copeland and
Horiuchi (17) competitive model. In the Lineweaver-Burk
plots, the double reciprocal of the Copeland andHoriuchi com-
petitive model (17) was fitted by non-linear regression to the
transformed data.
In both AdoMet and DNA competition assays, for each sub-
strate concentration, the IC50 of the tested compound was cal-
culated by non-linear regression fitting with sigmoidal dose-
response (variable slope) with constrained top and bottom at
100 and 0% of inhibition, respectively. All the non-linear and
linear regressions were performed on GraphPad Prism 4.03
(GraphPad Software).
Tm Assay—DNA thermal denaturation experiments were
conducted as described in Mergny and Lacroix (18). Hairpin
DNA duplexes hp_2_CG (5-TATATACGTACGGTGTT-
TTCACCGTACGTATATA-3) containing 2 CpG sites, hp_
1_CG (5-TATATACGTACTGTGTTTTCACAGTACGTA-
TATA-3) containing 1 CpG site, and hp_0_CG (5-TATATA-
TGTACTGTGTTTTCACAGTACATATATA-3) containing
no CpG site were used at 2M in the absence or presence of the
inhibitor in the Tm assay buffer (100 mM NaCl, lithium cacod-
ylate 20 mM, pH 7.2). The temperature at which 50% of the
duplex is denatured,Tm, was calculated as previously described
(18). Means of at least two experiments with the corresponding
S.E. are reported.
DNase I Footprinting—DNase I footprinting experiments
were performed essentially as described in Lemster et al. (19)
and Racané et al. (20). Briefly, the 117- and 265-bp DNA frag-
ments were obtained from EcoRI and PvuII double digestion of
the pBS plasmid (Stratagene, La Jolla, CA). The generatedDNA
fragments was 3-end-labeled for 30min at 37 °C using 10 units
of Klenow enzyme (New England BioLabs) and [-32P]dATP
(3000Ci/mmol, PerkinElmer Life Sciences) before isolation on
a 6% polyacrylamide gel under native conditions. The radiola-
beled 117- and 265-bp DNA fragments were cut off from the
gel, crushed, dialyzed overnight against 400 l of elution buffer
(10mMTris-HCl, pH 8.0, 1mMEDTA, 100mMNaCl), and then
separated from polyacrylamide gel by filtration through a Mil-
lipore 0.22-m membrane followed by ethanol precipitation.
Appropriate concentrations of the various tested compounds
were incubatedwith the 117- or 265-bp radiolabeledDNA frag-
ments for 15 min at 37 °C to ensure equilibrium before the
addition of 1 unit/l of DNase I in appropriate buffer for 3 min
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of digestion. The reactionwas stopped by ethanol precipitation.
The digested DNAs were subsequently dissolved in 4 l of
denaturing loading buffer (80% formamide solution containing
tracking dyes), heated for 4 min at 90 °C, and chilled 4 min on
ice before electrophoresis for 90 min at 65 watts on a 8% dena-
turing polyacrylamide gel in Tris/borate/EDTA buffer. Finally,
gels were soaked in 10% acetic acid, transferred to Whatman
No. 3MM paper to be dried under vacuum at 80 °C, and
exposed overnight at room temperature on phosphor-imaging
storage screens. The identity of the bases from each DNA frag-
ment was established from comparison of the relative position
of the bands to the guanine sequencing standard (G-track) clas-
sically obtained using dimethyl sulfate and piperidine treat-
ment of the same DNA fragment.
Differential Scanning Fluorimetry Assay—Experiments were
conducted using a CFX384TMReal-Time System (C1000 Ther-
mal cycler, Bio-Rad CFXManager 2.0 Software, Bio-Rad). The
samples were heated at 0.1 °C/s, from 10 to 80 °C. The fluores-
cence intensity was plotted as a function of the temperature.T1⁄2
was given by the inflection point of the fluorescence curve.T1⁄2
was calculated by subtracting the t1⁄2 in the absence of the com-
pound to the T1⁄2 in the presence of the compound in the same
condition (i.e. in the presence of other partners DNA and/or
AdoMet).
The protein was scanned to assess suitability of the method,
and the lowest concentration of DNMT1 protein needed to
generate a strong signal was determined to be 2.5 M. Com-
pound concentrations varied between 5 and 200 M. The DNA
duplex used in the enzymatic assays was chosen and added at 5
M. The AdoMet cofactor was added at a final concentration of
5M or not. The SYPRO orange dye (Invitrogen) was diluted to
1/400th in each sample. Each experiment was repeated for at
least two times in duplicate. Means of at least two experiments
are displayed with the corresponding S.E.
DNA Duplex and DNMT1 Gel Shift Assays—4 l of com-
pounds or 1% of DMSO, 0.5 M 6-carboxyfluorescein 5-la-
beled DNA duplex used in the DNMT1 enzymatic assay, and 5
M AdoMet were added in each well and incubated for 30 min
at 37 °C with or without 2.5 M DNMT1. Samples were loaded
on a 0.7% agarose gel and migrated for 50 min at 135 V in 1
Tris/borate/EDTA electrophoresis buffer. Gels were analyzed
with the Typhoon trio of GE Healthcare with appropriated
filters.
RESULTS
SGI-1027 and Its Analogs Share DNA-competitive and
AdoMet Non-competitive Behavior on DNMT1—We recently
developed a new DNMT1 inhibition assay in homogenous
phase that allows to study the mechanism of action of potent
inhibitors of DNMT1 by carrying out enzymatic studies (16).
We decided here to apply it to the study of 4-aminoquinoline
SGI-1027, a well described inhibitor of DNMTs, and two
analogs that we have recently synthesized, 31 and 5 (Fig. 1)
(13, 14). Interestingly, the latter is a position isomer of SGI-
FIGURE 1. Chemical structures and enzymatic activities of SGI-1027 and its analogs. The IC50 against DNMT3Acat and DNMT1 are reported. For 19, the
percentages of inhibitionofDNMT3Acat orDNMT1are displayed. Themeans of twoexperimentswith the corresponding S.E. are shown. The compoundswere
named accordingly to the nomenclature of the respective articles.
Mechanism of Inhibition of SGI-1027 and Analogs
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1027, in which the aminopyrimidine and the phenyl group
are attached in meta of the amide function and not in para,
as in SGI-1027 (Fig. 1). Derivative 31 contains a pyridine
instead of the pyrimidine cycle and an inverted amide at the
center. The three compounds are potent inhibitors of
DNMT1 (IC50 of 10 M for SGI-1027, 15 M for 31, and 5.7
M for 5, Fig. 1 and Table 1) and of DNMT3Acat (IC50 of 0.8,
0.9, and 0.7 M, respectively; Fig. 1 and Table 1) (14). The
assay that we developed was particularly suitable to carry out
competition experiments on DNMT1, which methylates
DNA with higher yields than DNMT3Acat. In addition, we
dispose of the full-length human DNMT1, containing all the
important domains for the interaction of the enzyme with
DNA and with the inhibitors (21), whereas we only disposed
of the C-terminal domain of DNMT3A (DNMT3Acat).
Therefore, full-length DNMT1 was chosen to perform all
further competition experiments.
First, we studied the behavior of the inhibitors to compete
with the DNA substrate of the enzyme in the DNMT1 enzy-
matic test. To analyzewhether the compoundswereDNAcom-
petitors or not, we performed non-linear regression with the
three models (competitive, non-competitive, and uncompeti-
tive inhibition) described byCopeland andHoriuchi (17). Inter-
estingly, DNA competition studies displayed unexpected
results (Fig. 2). Velocity plots against substrate concentration
did not follow the Michaelis-Menten behavior and presented a
sigmoidal character that was particularly significant at high
inhibitor concentrations (Fig. 2, A–C). This phenomenon
resulted in a deformation of the Lineweaver-Burk plots (Fig. 2,
D–F). Indeed, at high inhibitor concentrations, points no lon-
ger displayed a linear behavior but rather an up-turning para-
bolic character that could be approximated with a quadratic
function. Copeland and Horiuchi (17) explained these features
as being characteristic of competitive inhibitors that might
interact with DNA.
In agreement with these competitive behaviors (22), the
measured IC50 of the compounds increased as the DNA con-
centration increased (data not shown). However, in the case of
substrate-inhibitor interactions, the IC50 analysis is not suf-
ficient to conclude whether SGI-1027 and its analogs are
DNA competitors or not (17). Thus, velocity plots, double-
reciprocal plots, and IC50 against [DNA]/KmDNA plots were
analyzed; all suggested a DNA competitive inhibition of
DNMT1 (Fig. 2 and data not shown). Moreover, concerning
compound 5, the sigmoid is so stretched to appear as aligned
points (Fig. 2B). This is a mathematical limit of the Copeland
and Horiuchi (17) model that occurs when nearly all the
inhibitor in solution is complexed to the substrate, in our
case the DNA, leading to an apparent straight line. This sug-
gested that compound 5 is a stronger DNA binder than 31
and SGI-1027.
In contrast, in AdoMet competition studies, each compound
presented aMichaelis-Menten behavior with hyperbolic veloc-
ity plots against the substrate concentration (Fig. 3, A–C).
Moreover, this was confirmed by the double-reciprocal plots
(Fig. 3D-F). As the Kmapp remained constant and the 1/Vmapp
increased with increasing inhibitor concentrations (data not
shown), SGI-1027 and its analogs resulted in AdoMet non-
competitive inhibitors of DNMT1. In addition, the overall
unchanged IC50 regardless of the AdoMet concentration con-
firmed this hypothesis (Fig. 3, G–I) (22).
Thus, our results showed that SGI-1027 and its analogs dis-
play AdoMet non-competitive behaviors in agreement with the
Michaelis-Menten model in experimental conditions in which
the DNA concentration is constant. On the other hand, the
three compounds seemed to be DNA competitors with devia-
tions from the Michaelis-Menten equation at high inhibitor
concentrations. As this phenomenonmight be characteristic of
the inhibitor interacting with the DNA, we next evaluated this
feature by using parent compound 19 as a negative control as it
inhibits neither DNMT1 nor DNMT3Acat.
SGI-1027 Interacts Weakly with DNA, and Compound 5
Binds Strongly to DNA—To study the interaction between the
compounds and DNA, we followed thermal denaturation of
short DNA duplexes by UV absorbance in the absence and in
the presence of the compounds. Three hairpin duplexes were
chosen containing no CpG site (hp_0_CG, Tm  68.0 °C), 1
CpG site (hp_1_CG, Tm  71.0 °C), and 2 CpG sites
(hp_2_CG, Tm 74.5 °C). Fig. 4,A–C, and Table 1 report the
differences observed in Tm (Tm) for the DNA duplexes
when in the presence of 19, SGI-1027, 31, and 5. No signif-
icant increase in the Tm value was observed when the nega-
tive control 19 was incubated with any of the DNA duplexes,
whereas SGI-1027 showed a slight increase of the Tm value
when incubated with hp_1_CG (Tm  1.0 °C). The data
with compounds 31 showed a higher S.E. because the mole-
cule was less soluble in DMSO. It showed a concentration
effect on the Tm of the duplexes (data not shown), suggesting
that the compound interacts weakly with DNA. Derivative 5
resulted to be a strong DNA ligand (Tm  4.0 °C, 3.0 °C,
and 1.5 °C for hp_0_CG, hp_1_CG, and hp_2_CG, respec-
tively). The interaction of 5 with the three DNA duplexes
TABLE 1
DNMT1andDNMT3Acat inhibitionactivityof SGI-1027and its analogsanddifferences in theTmvaluesof theduplexes in thepresenceand in the
absence of the compounds (Tm)
The concentrations (M) at which 50% of the methylation activity is inhibited (IC50) are reported for DNMT3Acat and DNMT1. For 19, the percentages of inhibition are
displayed. The difference in Tm (Tm in °C) in the presence of 10 M of inhibitors and in their absence is reported for each duplex. Means of at least two experiments with
the corresponding standard errors are reported. The means of measured Tm are displayed in parentheses (°C).
Compounds
IC50 Tm (measured Tm in °C) at 10 M
DNMT3Acat DNMT1 hp_2_CG hp_1_CG hp_0_CG
M °C
SGI-1027 0.8 M 0.1 M 10 M 1 M 0.5 0.0 (74.0) 1.0 0.0 (72.0) 0.5 0.0 (68.5)
5 0.7 M 0.5 M 5.7 M 0.2 M 1.5 0.0 (76.0) 3.0 0.0 (74.0) 4.0 0.0 (72.0)
31 0.9 M 0.2 M 15 M 3 M 0.3 0.3 (74.8) 1.1 0.2 (72.1) 1.6 0.4 (69.6)
19 10% of inhibition at 10 M 10% of inhibition at 10 M 0.5 0.0 (75.0) 0.5 0.0 (71.5) 0.3 0.3 (68.3)
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was also monitored at 375 nm, a wavelength at which the
ligand absorbs, allowing the monitoring of specific changes
related to the ligand (23). Inverted transitions were observed
for the three duplexes with the same temperature depen-
dence as that observed at 260 nm. This inverted transition
for duplex hp_2 with compound 5 is shown in Fig. 4D and is
representative of experiments with the other duplexes (data
not shown). This transition was not observed with SGI-1027
and the other compounds (data not shown). This indicates
that, upon duplex melting (as observed at 260 nm), the
absorbance properties of 5 are concomitantly modified,
strongly supporting that 5 interacts with DNA. Hence, the
most potent inhibitor of full-length DNMT1 is also the
strongest DNA binder (Table 1).
Next, for compounds that interact with DNA, an interest-
ing issue is the selectivity of the compounds toward the DNA
sequence. This point could not be addressed upon use of the
three hairpin duplexes because they melt at different tem-
peratures. Thus we addressed it by DNase I footprinting
analysis.
This technique can show where the compound binds on a
DNA fragment of a known sequence. Two DNA sequences
were analyzed: a 265-bp DNA fragment containing some
AT-rich sites and two CpG sites and a 117-bp DNA fragment
FIGURE 2. DNA-competition studies with SGI-1027 and its analogs in a DNMT1 enzymatic assay. A–C, initial velocity plots against DNA concentra-
tions for different concentrations of SGI-1027 (A), 5 (B), and 31 (C). Squares represent points in the absence of the inhibitor. For SGI-1027 (A): triangles,
circles, empty triangles, diamonds, and crosses represent 5.6, 10, 14.7, 21.5, and 32 M, respectively. For 5 (B): triangles, circles, empty triangles, diamonds,
and crosses represent 3.2, 4.2, 5.6, 7.5, and 10M, respectively. For 31 (C): triangles, circles, empty triangles, and diamonds represent 10, 25, 40, and 55M,
respectively. Plain lines represent fittings with the Copeland and Horiuchi (17) competitive model. D–F, Lineweaver-Burk (or double reciprocal) plots for
SGI-1027 (D), 5 (E), and 31 (F). For the corresponding concentrations, the same legend is applied as for A–C. Plain lines represent fittings with the
double-reciprocal of Copeland and Horiuchi (17) competitive model. The means of two experiments are displayed with the corresponding S.E.
Mechanism of Inhibition of SGI-1027 and Analogs
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with several CpG sites in a less AT-rich environment
(Fig. 5).
Both DNase I footprinting gels and densitometric analyses
confirmed that SGI-1027 binds weakly to DNA showing some
noise (as poor and nonspecific DNA binding) in the differential
cleavage pattern, as does compound19. Compound31partially
protected the DNA from DNase I digestion at concentrations
up to 2.5M, with a preference for A/T stretches on the 265-bp
DNA fragment (Fig. 5, A and C) but shifting to CpG binding
(positions 37–38 and 50–51) on the 117-bp DNA fragment.
However, the protection was weak. Noteworthy, for both SGI-
1027 and 31, we could not test higher concentrations than the
reported ones as it resulted in cleavage inhibition (smearing),
which interfered with sequence selectivity analysis.
Compound 5 clearly showedmuch stronger footprints sur-
rounded by huge cleavage enhancements as evidenced on the
gels by strongly digested bands (Fig. 5, A and C) and on the
densitometric analyses by positive differential cleavage cal-
culated relatively to control lanes 0 in the absence of the
compounds (Fig. 5, B and D). Clearly, in agreement with the
Tm analysis, 5 is the strongest DNA binder of the series
showing binding to CpG dinucleotides (positions 37–38 and
50–51, Fig. 5D; position 88–89 evidenced at 10 M, Fig. 5B).
The strong DNase I cleavage enhancements observed may
reflect some distortion of the DNA helix induced by the
binding of 5 (24).
Both DNA duplex thermal denaturation and DNase I foot-
prints showed that 19 does not interact with DNA and that
SGI-1027 and 31 display weak interaction. In contrast, 5 is
clearly the strongest DNA ligand and the most potent inhibitor
of DNMT1. Next, we investigated whether the compounds
directly interact with DNMT1 by using thermal shift analysis of
the protein unfolding temperature.
Compound 5 Interacts with DNMT1 Only When the DNA Is
Present—In the fluorescence-based thermal shift assay (differ-
ential scanning fluorimetry), the ability of a molecule to stabi-
lize or destabilize the protein during its thermal unfolding is
quantified by its thermal shift (T1⁄2): the difference in the pro-
FIGURE 3. AdoMet competition studies of SGI-1027 and its analogs in a DNMT1 enzymatic assay. A–C, initial velocity plots against AdoMet
concentrations for different concentrations of SGI-1027 (A), 5 (B), and 31 (C). Squares represent points without inhibitor. For SGI-1027 (A): triangles,
circles, empty triangles, diamonds, and crosses represent 3.2, 5.6, 10, 14.7, and 21.5 M, respectively. For 5 (B): triangles, circles, empty triangles, diamonds,
and crosses represent 3.2, 4.2, 5.6, 7.5, and 10 M, respectively. For 31 (C): triangles, circles, empty triangles, diamonds, and crosses represent 3.2, 5.6, 10,
20, and 32M, respectively. Plain lines represent fittings with the Michaelis-Mentenmodel.D–F, Lineweaver-Burk (double reciprocal) plots for SGI-1027
(D), 5 (E), and 31 (F). For the corresponding concentrations, the same legend is applied as for A–C. Plain lines represent fittings with the linear model to
the data. G–I, IC50 of SGI-1027 (G), 5 (H), and 31 (I), respectively, as a function of [AdoMet]/Km
AdoMet. As the fittings according to a linear model were not
significantly different from zero (p  0.05), they were not displayed. The means of two experiments are displayed with the corresponding S.E.
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tein unfolding temperature in the presence and absence of the
ligand.
The DNMT1 unfolding temperature was determined to be
46.8  0.1 °C in absence of any ligand. No variation or T1⁄2 of
3.4 0.2 °C was observed when DNMT1 was incubated with 5
M AdoMet or 5 M DNA, respectively (data not shown).
Finally, in the presence of bothDNA andAdoMet, theT1⁄2 was
6.1 0.4 °C suggesting a cooperation between the two ligands
(data not shown). In the presence of 200M inhibitor5 (Fig. 6A)
no variationwasmeasured in the absence ofDNAandAdoMet;
in contrast a strong destabilization was observed when the
DNA andAdoMet were present in the solution (T1⁄26.6
0.2 °C). Thus compound 5 did not directly interact with
DNMT1 but needed the formation of the DNMT1-AdoMet-
DNA enzymatic complex. This observation was confirmed
when each substrate was added separately (Fig. 6B). In fact, a
variation in the T1⁄2 of DNMT1 was only observed when the
DNAduplex was present in addition to compound 5. Notewor-
thy, the destabilization was strongest when AdoMet was also
present. In addition, a dose-response curvewas obtained for the
T1⁄2 of the enzymatic complex with the increase in compound
5 concentration (Fig. 6C). Similar results were obtained on
DNMT3Acat (data not shown).
The other compounds interacted weakly with DNMT1
alone or in the presence of its two substrates (DNA and
AdoMet), with the exception of SGI-1027, which showed a
strong destabilization in the presence of the ternary complex
(T1⁄2  7.1  0.2 °C, Fig. 6A). Compounds 19 and SGI-
1027 presented a weak destabilizing effect on DNMT1
alone (Fig. 6A) that could be observed also on the ternary
complex.
Noteworthy, in agreement with the AdoMet non-compet-
itive behavior observed in the enzymatic studies for SGI-
1027, the destabilization of the DNMT1 and of the DNMT1-
AdoMet-DNA complexes was little dependent on the
AdoMet concentration (Fig. 6D). The slight effect observed
mainly arises from the stabilizing effect of increasing con-
centration of AdoMet on the DNMT1-DNA complex (data
not shown).
Compound 5 Destabilizes the DNMT1-DNA Complex—To
further explore the destabilization of the enzymatic complex by
the compounds, DNMT1 was complexed on a fluorescein-la-
beled DNA duplex in the absence or in the presence of the
different compounds and migrated on an agarose gel (Fig.
7A). Only compound 5 destabilized the DNMT1-DNA com-
plex with the appearance of the free duplex as the concen-
tration of the compound increased. In addition, heat dena-
turing experiments at 40 °C showed that the DNMT1-DNA
complex is dissociated faster in the presence of compound 5
(Fig. 7B).
DISCUSSION
Our data indicate that SGI-1027 and its two analogs, 5
and 31, are inhibitors of DNMT3Acat and DNMT1. Com-
pound 5 is the most potent inhibitor of DNMT1 among the
three. These compounds behaved as AdoMet non-competi-
FIGURE 4.Tm value for the hairpin duplexes in the presence of SGI-1027, compound 19, 31 and 5. A–C, each duplex (hp_0_CG, panel A; hp_1_CG, panel
B; hp_2_CG, panel C) was incubatedwith 10M 19 (vertically stripped bars), SGI-1027 (white bars), 31 (horizontally strippedbars), and 5 (gray bars). Themean of
at least two experiments is reported with the corresponding S.E.D, the absorbance of the bases at 260 nm (white circles) and of compound 5 at 375 nm (black
diamonds) is recorded for the duplex in the presence of compound 5 as a function of the temperature (°C).
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tive inhibitors of DNMT1 and, rather, displayed non-Mi-
chaelian behaviors in DNA competition studies on DNMT1,
which is characteristic of DNA competitive inhibition with
DNA-inhibitor interactions (17). These results are in dis-
agreement with previous reports describing a AdoMet com-
petitor behavior for SGI-1027 (9, 10). Datta et al. (9) ana-
lyzed only parts of the velocity plots against AdoMet
concentration; a plateau was not reached in their experimen-
tal conditions rendering the interpretation more difficult.
Fagan et al. (10) conducted competition experiments on a
truncated form of DNMT1 (residues: 621–1600 amino acids)
missing the replication focus targeting sequence (RFTS)
domain. Importantly, this domain was previously described
to be an endogenous DNA competitive inhibitor of DNMT1
(25) and to bind to the DNA binding pocket of DNMT1 (26).
Thus, it is not surprising that DNA competition studies on
truncated DNMT1 are different from ours carried out on the
full-length enzyme. Regarding the deviations from the
Michaelis-Menten model observed in our DNA competition
experiments, they can also result from other causes than
substrate-inhibitor interactions. For example, they can be the
consequences of tight binding or time-dependent inhibition.
We cannot exclude these other hypotheses. However, we
experimentally observed that the compounds interact with
DNA and in particular compound 5, supporting this inhibition
mechanism. Indeed compound 5, the most potent inhibitor
(Table 1) on DNMT1, is a strong DNA binder (Table 1 and Fig.
4), whereasSGI-1027 and 31 interact onlyweakly. These deriv-
atives present a preference for A/T stretches, G/C-rich
stretches, and certain CpG sites in the 117-bp DNA fragment
studied here (Fig. 5). Interestingly, the change from the para to
the meta bonds from SGI-1027 to 5 increased the DNA bind-
ing properties, suggesting a better fitting in the DNA groove
(27). Finally, for compound 5, wewere able to establish that this
molecule only interacts with DNMT when the DNA is present
(Fig. 6) and induces a destabilization of the DNMT1-AdoMet-
FIGURE 5. DNase I footprinting analysis. 265 bp (A and B) or 117 bp (C and D) radiolabeled DNA were incubated with increasing concentration (M) of the
indicated compounds before DNase I digestion and separation of the digested fragments on a denaturing gel (A-C) for further densitometric analysis (B–D).
Gray lanes and gray boxes localize footprints and CpG dinucleotides, respectively.
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DNA complex (Fig. 7). SGI-1027 was also shown to be able to
destabilized the DNMT1 in the presence of DNA and AdoMet
by differential scanning fluorimetry (Fig. 6).
In conclusion, both enzymatic assays and biophysical studies
indicate that the most potent inhibitor of DNMT1, compound
5, inhibits DNMT by interacting with DNA and destabilizing
the enzymatic complex.
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